Vanda Pharmaceuticals (VNDA)

Jan 15, 2026, 5:26 PM EST - 19 days ago

Vanda Pharmaceuticals Inc. (VNDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 9:31 AM EST - 26 days ago

Vanda and Exante Data Combine in Strategic Merger

Jan 8, 2026, 7:00 AM EST - 26 days ago

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

Jan 1, 2026, 7:40 AM EST - 4 weeks ago

Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus

Dec 31, 2025, 10:57 AM EST - 4 weeks ago

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval

Dec 30, 2025, 6:30 PM EST - 5 weeks ago

US FDA approves Vanda Pharmaceuticals' motion sickness drug

Dec 30, 2025, 6:13 PM EST - 5 weeks ago

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness

Dec 15, 2025, 7:00 AM EST - 7 weeks ago

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB

Dec 11, 2025, 5:02 PM EST - 7 weeks ago

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

Dec 4, 2025, 4:21 PM EST - 2 months ago

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness

Nov 28, 2025, 7:00 AM EST - 2 months ago

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

Nov 21, 2025, 3:31 AM EST - 2 months ago

Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality

Nov 18, 2025, 10:49 AM EST - 2 months ago

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

Nov 17, 2025, 6:37 PM EST - 2 months ago

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Nov 5, 2025, 5:00 PM EST - 3 months ago

Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference

Oct 29, 2025, 10:16 PM EDT - 3 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 4:01 PM EDT - 3 months ago

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 4:30 PM EDT - 3 months ago

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

Oct 8, 2025, 8:00 AM EDT - 4 months ago

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Oct 1, 2025, 5:02 PM EDT - 4 months ago

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

Sep 25, 2025, 8:00 AM EDT - 4 months ago

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Aug 29, 2025, 3:21 PM EDT - 5 months ago

Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement

Aug 28, 2025, 5:23 PM EDT - 5 months ago

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 5 months ago

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Aug 21, 2025, 4:40 PM EDT - 5 months ago

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

Aug 18, 2025, 7:00 AM EDT - 6 months ago

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Jul 31, 2025, 4:45 PM EDT - 6 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 7:30 AM EDT - 6 months ago

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 4:45 PM EDT - 6 months ago

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jun 10, 2025, 8:00 AM EDT - 8 months ago

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

May 27, 2025, 9:00 AM EDT - 9 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 16, 2025, 5:30 PM EDT - 9 months ago

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 7, 2025, 7:55 PM EDT - 9 months ago

Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:01 PM EDT - 9 months ago

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 9 months ago

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

May 2, 2025, 8:46 AM EDT - 9 months ago

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Apr 23, 2025, 3:52 PM EDT - 10 months ago

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Apr 7, 2025, 8:00 AM EDT - 10 months ago

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

Feb 24, 2025, 7:00 AM EST - 1 year ago

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Feb 13, 2025, 10:29 PM EST - 1 year ago

Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 4:01 PM EST - 1 year ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 5, 2025, 4:30 PM EST - 1 year ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Jan 27, 2025, 7:00 AM EST - 1 year ago

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Jan 8, 2025, 4:17 PM EST - 1 year ago

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Dec 20, 2024, 1:26 PM EST - 1 year ago

Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity

Dec 20, 2024, 9:13 AM EST - 1 year ago

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera